Esperion Therapeutics (ESPR) Long-Term Investments (2013 - 2019)

Esperion Therapeutics' Long-Term Investments history runs 7 years deep, the most recent figure standing at $30.9 million for Q1 2019.

• Quarterly Long-Term Investments fell 27.05% year-over-year to $30.9 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $30.9 million (down 27.05% YoY) and the FY2018 annual result came in at $243000.0, down 99.67% from the prior year.
• Long-Term Investments was $30.9 million for Q1 2019 at Esperion Therapeutics, up from $243000.0 in the prior quarter.
• Across five years, Long-Term Investments topped out at $105.7 million in Q3 2017 and bottomed at $243000.0 in Q4 2018.
• A 5-year average of $50.4 million and a median of $44.6 million in 2015 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2015 — Long-Term Investments soared 1616.54% — and 2018, when it sank 99.67%.
• Esperion Therapeutics' Long-Term Investments stood at $80.3 million in 2015, then tumbled by 61.52% to $30.9 million in 2016, then jumped by 137.56% to $73.4 million in 2017, then sank by 99.67% to $243000.0 in 2018, then soared by 12614.4% to $30.9 million in 2019.
• Business Quant data shows ESPR's Long-Term Investments at $30.9 million in Q1 2019, $243000.0 in Q4 2018, and $5.2 million in Q3 2018.